About: Chloroquine dosage regimens in patients with COVID-19: safety risks and optimization using simulations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chloroquine dosage regimens in patients with COVID-19: safety risks and optimization using simulations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Chloroquine dosage regimens in patients with COVID-19: safety risks and optimization using simulations
Creator	Ismailos, George Karalis, Vangelis Karatza, Eleni
source	Elsevier; Medline; PMC
abstract	Currently no specific medicinal treatment exists against the new SARS-CoV2 and chloroquine is widely used, since it can decrease the length of hospital stay and improve the evolution of the associated COVID-19 pneumonia. However, several safety concerns have been raised from chloroquine use due to the lack of essential information regarding its dosing. The aim of this study is to provide a critical appraisal of the safety information regarding chloroquine treatment and to apply simulation techniques to unveil relationships between the observed serious adverse events and overdosing, as well as to propose optimized dosage regimens. The dose related adverse events of chloroquine are unveiled and maximum tolerated doses and concentration levels are quoted. Among others, treatment with chloroquine can lead to severe adverse effects like prolongation of the QT interval and cardiomyopathy. In case of chloroquine overdosing, conditions similar to those produced by SARS-CoV2, such as pulmonary oedema with respiratory insufficiency and circulatory collapse, can be observed. Co-administration of chloroquine with other drugs for the treatment of COVID-19 patients, like azithromycin, can further increase the risk of QT prolongation and cardiomyopathy. For elder patients there is a high risk for toxicity and dose reduction should be made. This study unveils the risks of some widely used dosing regimens and binds the observed serious adverse events with dosing. Based on simulations, safer alternative dosage regimens are proposed and recommendations regarding chloroquine dosing are made.
has issue date	2020-05-21(xsd:dateTime)
bibo:doi	10.1016/j.ssci.2020.104842
bibo:pmid	32501367
has license	no-cc
sha1sum (hex)	113af91a0065f818a85d7bb33c4983432bf12d5b
schema:url	https://doi.org/10.1016/j.ssci.2020.104842
resource representing a document's title	Chloroquine dosage regimens in patients with COVID-19: safety risks and optimization using simulations
has PubMed Central identifier	PMC7241328
has PubMed identifier	32501367
schema:publication	Saf Sci
resource representing a document's body	covid:113af91a0065f818a85d7bb33c4983432bf12d5b#body_text
is schema:about of	named entity 'Chloroquine' named entity 'safety' named entity 'patients' named entity 'safety' named entity 'Chloroquine' named entity 'doi' named entity 'Chloroquine' named entity 'doi' named entity 'safety risks' named entity 'COVID-19' named entity 'safety risks' named entity 'prolongation of the QT interval' named entity 'hypoglycemia' named entity 'fluoxetine' named entity 'cardiomyopathy' named entity 'Cardiomyopathy' named entity 'sotalol' named entity 'volumes of distribution' named entity 'heart failure' named entity 'dizziness' named entity 'toxicity' named entity 'WHO' named entity 'overdose' named entity 'SARS-CoV2' named entity 'steady state' named entity 'chloroquine' named entity 'liver' named entity 'kidney' named entity 'North Americans' named entity 'genetic variability' named entity 'covariate' named entity 'volume of distribution' named entity 'FDA' named entity 'residence time' named entity 'plasma levels' named entity 'chloroquine' named entity 'US FDA' named entity 'cardiomyopathy' named entity 'circulatory collapse' named entity 'SARS-CoV-2' named entity 'toxic effects' named entity 'fluconazole' named entity 'liver function' named entity 'carbamazepine' named entity 'body surface area' named entity 'mechanical ventilation' named entity 'toxicity' named entity 'antimalarial' named entity 'hypoglycemia' named entity 'pulmonary oedema' named entity 'Chloroquine' named entity 'amiodarone' named entity 'chloroquine' named entity 'toxicity' named entity 'respiratory insufficiency' named entity 'cardiac arrhythmias' named entity 'supportive treatment' named entity 'FDA' named entity 'plasma' named entity 'overdosage' named entity 'plasma' named entity 'bound to plasma proteins' named entity 'chlorpromazine' named entity 'COVID' named entity 'health care' named entity 'prolongation of the QT interval' named entity 'blood glucose levels' named entity 'toxicity' named entity 'toxicity' named entity 'vasopressin' named entity 'chloroquine' named entity 'volume of distribution' named entity 'immunological response' named entity 'virus-cell fusion' named entity 'chemoprophylaxis' named entity 'anti-inflammatory' named entity 'plateau levels' named entity 'Parenteral' named entity 'escitalopram'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software